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A nationwide survey was conducted in
Switzerland to assess the quality level of osteo-
porosis management in patients aged 50 years or
older presenting with a fragility fracture to the
emergency ward of the participating hospitals.
Eight centres recruited 4966 consecutive pa-
tients who presented with one or more fractures
between 2004 and 2006. Of these, 3667 (2797
women, 73.8 years old and 870 men, 73.0 years
old in average) were considered as having a
fragility fracture and included in the survey.
Included patients presented with a fracture of
the upper limbs (30.7%), lower limbs (26.4%),
axial skeleton (19.5%) or another localisation, in-
cluding malleolar fractures (23.4%). Thirty-two
percent reported one or more previous fractures
during adulthood. Of the 2941 (80.2%) hospi-
talised women and men, only half returned home
after discharge. During diagnostic workup, dual
x-ray absorptiometry (DXA) measurement was
performed in 31.4% of the patients only. Of those
46.0% had a T-score ≤–2.5 SD and 81.1% ≤–1.0
SD. Osteoporosis treatment rate increased from
26.3% before fracture to 46.9% after fracture in
women and from 13.0% to 30.3% in men. How-
ever, only 24.0% of the women and 13.8% of the
men were ﬁnally adequately treated with a bone
active substance, generally an oral bisphospho-
nate, with or without calcium / vitamin D supple-
ments. A positive history of previous fracture vs
none increased the likelihood of getting treat-
ment with a bone active substance (36.6 vs 17.9%,
D 18.7%, 95% CI 15.1 to 22.3, and 22.6 vs 9.9%,
D 12.7%, CI 7.3 to 18.5, in women and men, re-
spectively).
In Switzerland, osteoporosis remains under-
diagnosed and undertreated in patients aged 50
years and older presenting with a fragility frac-
ture.
Key words: discharge status; DXA; epidemiology;
fragility fractures; osteoporosis; pharmacological treat-
ment
Summary
Osteoporosis is a systemic skeletal disease
characterised by low bone mass and microarchi-
tectural deterioration of bone tissue, with a conse-
quent increase in bone fragility and susceptibility
to fracture [1]. Osteoporotic fractures represent a
considerable and growing burden to patients, so-
ciety and health-care ﬁnancing [2, 3]. These frac-
tures can occur in virtually any bone, in both gen-
ders, typically after a low-energy trauma (fragility
fractures) and are a major risk factor for subse-
quent fractures [4–7] and increased mortality [8].
The diagnosis of osteoporosis relies on indi-
vidual fracture risk assessment and clinical exami-
nation, followed by bone mineral density (BMD)
measurement with DXA [9], the diagnostic facili-
ties being readily available throughout Europe
[10], including Switzerland. Efﬁcacious treatment
options, such as bisphosphonates, SERMs and
teriparatides have been proven to reduce fracture
risk in adequately designed, randomised, con-
trolled fracture endpoint trials [11] and shown to
be cost-effective [12]. Furthermore, there is a
general worldwide consensus that patients aged
50 years and older, presenting with a fragility
fracture should undergo diagnostic workup, ac-
tively seeking for osteoporosis, and beneﬁt from
appropriate measures aiming at reducing the risk
for further fractures [1, 9].
Despite several initiatives reporting improved
disease management [13–16], recent contribu-
tions from different countries have shown that
even after a dramatic inaugural event such as a
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fracture, and even a hip fracture, osteoporosis re-
mains frequently undiagnosed and untreated
[17–20].
The aim of the present survey was to assess
the nationwide quality level of management of
patients with an acute fracture with regard to os-
teoporosis diagnosis and treatment, in order to
establish the baseline for future quality improve-
ment projects to be implemented at the individual
hospital level.
Material and methods
Between 2004 and 2006, eight centres recruited con-
secutive patients with fracture.Three participating hospi-
tals were University Hospitals (Basel, Berne, and Lau-
sanne), three cantonal hospitals (Fribourg, Lucerne, and
St Gallen) and two regional hospitals (Estavayer and
Riaz). Seventy percent of the patient reports originated
from the German speaking part of Switzerland and the
remainder 30% from the French speaking part, a distri-
bution which is compatible with that of the Swiss popula-
tion. When taking additionally into account that Swiss
University hospitals also fulﬁl the role of cantonal and/or
regional hospitals in their zone of inﬂuence, centres par-
ticipating in this survey can be considered as being repre-
sentative for Switzerland as a whole.All centres had direct
access to a DXA device for BMD measurement, which
could be performed either during hospitalisation or on
appointment after discharge.
Consecutive fracture patients were recruited over
8 to 16 months, depending on cantonal requirements and
individual differences in time needed for implementing
the survey. In each participating centre, a nurse was dedi-
cated to project management and follow-up, whereby no
strict criteria applied. Cantonal ethical review committee
approval was obtained for each participating site if re-
quired, whereby one canton required preliminary written
informed consent. In all other centres oral approval for
data collection was obtained from the patient by either
the dedicated nurse or the resident in charge. For ambu-
latory patients, approval was obtained either during the
consultation or during the week thereafter by follow-up
phone call. Patients also gave their approval that missing
data be obtained from their treating physician or their
family. No data other than those relevant to the treatment
of the current fracture event were retrieved from patient
records. Whenever possible, missing data (such as BMD
values if the DXA examination was made on appointment
or the history of previous fracture) were obtained by call-
ing the patient, his family or his treating physician.
All clinical fractures occurring in male and female
patients aged 50 years and older were prospectively docu-
mented with a predeﬁned standardised questionnaire ad-
ministered by either the study nurse or the resident in
charge. For all patients, gender, fracture localisation, type
of orthopaedic treatment (ambulatory vs hospitalisation),
and previous history of fracture during adulthood were
recorded. Exclusion criteria were: patients not willing to
participate, fractures after a high velocity trauma, patho-
logical fractures, typically non-osteoporotic fractures
(such as fractures of the ﬁnger or the toe), poor general
health, and neuropsychiatric disorder with cognitive dys-
function (such as Alzheimer’s disease). All remaining pa-
tients were included in the cohort and their discharge sta-
tus, diagnostic workup (clinical status, X-Rays and BMD
measurement) and pharmacological treatment measures
against osteoporosis (before and after the fracture event)
were recorded.
Data analysis was performed with descriptive statis-
tics methods, such as the calculation of means, standard
deviations, proportions and 95% conﬁdence intervals
(CI) of the differences (D) between groups for formal
comparisons, using a StatsDirect® software version 2.6.5.
Results
Over an average observation period of 12.2
months, 5395 fractures were recorded in 4966
consecutive female (N = 3598) and male (N =
1368) patients aged 50 years and older in the eight
participating hospitals. Mean age was 72.5 ± 12.1
years; women were slightly older than men (73.9 ±
11.8 vs 69.0 ± 12.1, respectively). The distribution
of all recorded fractures by fracture localisation
and by gender is shown in table 1. Of all recorded
fracture patients, 1299 (26.2%) were excluded for
reasons shown in ﬁgure 1. The remaining 3667
women and men with an acute fragility fracture
(on average 73.8 ± 11.6 and 70.0 ± 12.1 years old,
respectively) were included in the analysis.
History of previous fracture
Overall, 1185 (32.3%) patients reported 1634
previous fractures during adulthood, correspond-
ing to an average of 1.38 previous fractures per
patient. Although these ﬁgures were similar across
genders (32.9% of women and 30.6% of men had
experienced a mean of 1.39 and 1.35 previous
fractures, respectively), previous fractures of the
upper limbs were more frequent in women than in
men (32.3 vs 21.7%, ∅ 10.6%, 95% CI 5.4 to
15.4), as shown in table 1.
Fractures at inclusion
In total, 3897 acute fractures were reported in
3667 patients, corresponding to a mean of 1.06
fractures per included patient. According to pre-
deﬁned categories, 30.7% of the acute fractures
were of the upper limb (distal forearm or proximal
humerus), 19.6% of the axial skeleton (spine, in-
cluding sacrum and ribs, or pelvis), 26.4% lower
limb fractures (femur or tibia), and 23.3% at an-
other localisation (such as distal humerus, elbow,
and malleolar fractures). Acute fractures of the
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upper limbs were more frequent in women than
in men (32.9 vs 23.7%, ∅ 9.2%, CI 5.9 to 12.3),
respectively). Details by fracture localisation and
gender are shown in table 1.
Discharge status
Of all patients with a fragility fracture, 2941
(80.2%) were hospitalised, women numerically
less often than men (79.3 vs 83.0%, ∅ –3.7%,
CI –6.5 to 0.0), respectively) while the remainder
were treated on an out-patient basis. The average
length of hospital stay was similar in women and
men (9.0 ± 6.9 and 9.3 ± 7.1 days, respectively).
After discharge 49.8% of the hospitalised patients
returned home, 32.7% went to a rehabilitation
clinic and the remainder 17.1% went either to a
nursing home or a retirement home, were trans-
ferred to another hospital, or died (0.4%), with no
signiﬁcant differences between women and men,
as shown in ﬁgure 2.
Osteoporosis diagnostic workup
Data were available for 2615 (71.3%) pa-
tients. DXA measurement was performed in 1152
(44.0%) of these, either alone (N = 501) or
in combination with clinical examination and/or
x-ray (N = 651), generally of the lumbar and tho-
racic spine aiming at identifying spinal osteoporo-
sis and/or associated vertebral fractures. In the
remaining 1463 (56.0%) patients, osteoporosis
diagnosis relied upon clinical examination (N =
1196), an x-ray (N = 219) or both (N = 48).When
DXA examination was performed (N = 1152), the
most frequently analysed regions of interest were
the lumbar spine (LS, 69.5%) and the femoral
neck (FN, 67.0%). In 495 patients (43.0%), three
regions or more (generally total hip, FN, and LS)
were analysed, in 46 patients (4.0%) two (gener-
ally LS and FN), and in 611 (53.0%) patients one
(generally LS or FN). Based on the deﬁnition of
osteoporosis proposed by the WHO [1, 9] and
considering the lowest measured T-score as diag-
nostic for osteoporosis, 46.0% of the patients
with an acute fragility fracture had severe osteo-
porosis (T-score 9 –2.5 SD in the presence of one
or more fragility fractures), 35.1% had osteopenia
(–2.5 < T-score 9 –1 SD), 14.4% were normal
(T-score > –1 SD), and no value was available for
4.5%. In women (N = 908), the prevalence of se-
vere osteoporosis and osteopenia was 47.5% and
34.7%, respectively. The corresponding preva-
lences in men (N = 244) were 40.6% and 36.5%,
respectively. Detailed mean T-score values by
fracture type and gender are shown in ﬁgure 3.
Pharmacological treatment against
osteoporosis (table 2)
Previous treatment: prior treatment of osteo-
porosis was reported in 849 patients (23.2%),
more frequently in women than in men (26.3 vs
Figure 1
OsteoCare survey
flowchart.
All consecutive patients aged 50+ with any fracture in any
participating hospital
N = 4966
Eligible for inclusion in the study?
Inclusion
N = 3667 (73.8%)
Orthopaedic
fracture treatment
Osteoporosis
diagnostic workup
Osteoporosis
treatment after
fragility fracture
Exclusion
N = 1299 (26.2%):
– No written consent N = 473 (36.4%)
– High velocity trauma N = 277 (21.3%)
– Poor general health N = 107 (8.2%)
– Pathological fracture N = 88 (6.8%)
– Severe cognitive dysfunction N = 87 (6.7%)
– No or other reason N = 236 (18.2%)
– Died N = 31 (2.4%)
Ambulatory
N = 726 (19.8%)
Hospitalisation
N = 2941 (80.2%)
DXA ± clinical ± X-ray
N = 1152 (31.4%)
No DXA (only clinical ± X-ray
N = 1463 (39.9%)
No data
N = 1052 (28.7%)
Any treatment
N = 1576 (43.0%)
No treatment or no data
N = 2091 (57.0%)
Calcium / Vit. D suppl. only
N = 784 (49.7%)
Bone active subst. ± suppl.
N = 792 (50.3%)
yES NO
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Women All recorded fractures Included fragility fractures
History of previous fracture Current fracture History of previous fracture Current fracture
N % N % N % N %
Total patients 1016 28.2% 3598 919 32.9% 2797
Total fractures 1396 3829 1275 2965
Fractures / patient (mean) 1.37 1.06 1.39 1.06
Fractures by localization
Distal forearm 302 21.6% 801 20.9% 271 21.3% 628 21.2%
Proximal humerus 161 11.5% 446 11.6% 141 11.1% 347 11.7%
Subtotal upper limbs 463 33.2% 1247 32.6% 412 32.3% 975 32.9%
Rib 45 3.2% 104 2.7% 44 3.5% 90 3.0%
Sacrum 7 0.5% 27 0.7% 5 0.4% 21 0.7%
Pelvis 52 3.7% 127 3.3% 48 3.8% 100 3.4%
Spine, lumbar 118 8.5% 256 6.7% 112 8.8% 207 7.0%
Spine, thoracic 126 9.0% 183 4.8% 120 9.4% 141 4.8%
Subtotal axial skeleton 348 24.9% 697 18.2% 329 25.8% 559 18.9%
Femur, neck 79 5.7% 280 7.3% 78 6.1% 254 8.6%
Femur, trochanter 106 7.6% 601 15.7% 82 6.4% 419 14.1%
Femur, shaft 0 0.0% 29 0.8% 0 0.0% 19 0.6%
Tibia, proximal 73 5.2% 128 3.3% 69 5.4% 95 3.2%
Subtotal lower limbs 258 18.5% 1038 27.1% 229 18.0% 787 26.5%
Other 215 15.4% 541 14.1% 202 15.8% 391 13.2%
Malleolar, lateral 53 3.8% 167 4.4% 51 4.0% 142 4.8%
Malleolar, median 37 2.7% 123 3.2% 33 2.6% 108 3.6%
No indication 19 1.4% 1 0.0% 17 1.3% 1 0.0%
Face 3 0.2% 10 0.3% 2 0.2% 2 0.1%
Skull 0 0.0% 5 0.1% 0 0.0% 0 0.0%
Subtotal all other 327 23.4% 847 22.1% 305 23.9% 644 21.7%
Men
Total patients 304 22.2% 1368 266 30.6% 870
Total fractures 404 1566 359 932
Fractures / patient (mean) 1.33 1.14 1.35 1.07
Fractures by localization
Distal forearm 50 12.4% 182 11.6% 44 12.3% 124 13.3%
Proximal humerus 37 9.2% 163 10.4% 34 9.5% 97 10.4%
Subtotal upper limbs 87 21.5% 345 22.0% 78 21.7% 221 23.7%
Rib 20 5.0% 70 4.5% 19 5.3% 38 4.1%
Sacrum 1 0.2% 4 0.3% 1 0.3% 0 0.0%
Pelvis 9 2.2% 74 4.7% 9 2.5% 35 3.8%
Spine, lumbar 43 10.6% 130 8.3% 37 10.3% 78 8.4%
Spine, thoracic 29 7.2% 98 6.3% 24 6.7% 54 5.8%
Subtotal axial skeleton 102 25.2% 376 24.0% 90 25.1% 205 22.0%
Femur, neck 33 8.2% 89 5.7% 31 8.6% 79 8.5%
Femur, trochanter 30 7.4% 206 13.2% 26 7.2% 129 13.8%
Femur, shaft 0 0.0% 4 0.3% 0 0.0% 1 0.1%
Tibia, proximal 22 5.4% 65 4.2% 19 5.3% 31 3.3%
Subtotal lower limbs 85 21.0% 364 23.2% 76 21.2% 240 25.8%
Other 101 25.0% 305 19.5% 93 25.9% 165 17.7%
Malleolar, lateral 10 2.5% 87 5.6% 7 1.9% 60 6.4%
Malleolar, median 6 1.5% 59 3.8% 5 1.4% 39 4.2%
No indication 7 1.7% 0 0.0% 7 1.9% 0 0.0%
Face 3 0.7% 18 1.1% 1 0.3% 2 0.2%
Skull 3 0.7% 12 0.8% 2 0.6% 0 0.0%
Subtotal all other 130 32.2% 481 30.7% 115 32.0% 266 28.5%
Table 1
Distribution of frac-
tures in all recorded
patients (n = 4966)
and in included pa-
tients with a fragility
fracture (n = 3667),
by gender and frac-
ture type. Some pa-
tients had multiple
fractures.
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Figure 2
Discharge status of
hospitalised patients
by gender (n = 2941).
Men (N = 244)
Women (N = 908)Figure 3
Mean of lowest
measuredT-scores,
by fracture type and
by gender (n = 1152). Malleolar, Iateral
Malleolar, median
Malleolar, median
No indication
Tibia, proximal
Other
Distal forearm
Procimal humerus
Femur, neck
Spine, lumbar
Femur, trochanter
Femur, shaft
Rib
Pelvis
Spine, thoracic
Sacrum
Sacrum
No indication
Tibia, proximal
Other
Distal forearm
Procimal humerus
Femur, neck
Spine, lumbar
Femur, trochanter
Femur, shaft
Rib
Pelvis
Spine, thoracic
Sacrum
Mean of lowest measuredT-score by fracture locallisation
Mean of lowest measuredT-score by fracture locallisation
Unknown
Died
Nursing home
Retirement home
Other hospital
Rehabilitation
Home
Fractures MeanT-
(N) score (SD)
69 –1.7
40 –1.5
1 –1.8
41 –2.0
108 –2.1
203 –2.2
113 –2.4
82 –2.4
77 –2.7
122 –2.9
2 –2.8
17 –3.2
33 –2.9
57 –3.0
10 –3.7
975 –2.3
Fractures MeanT-
(N) score (SD)
16 –1.6
15 –2.3
0 –
8 –1.2
45 –1.7
29 –2.9
32 –2.2
21 –2.1
25 –2.7
38 –2.2
0 –
9 –2.2
7 –2.4
19 –2.5
0 –
264 –2.2
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13.0%, ∅ 13.3%, CI 10.5 to 16.0) as shown in
table 2. Patients with a positive history of previ-
ous fracture were more likely to have been pre-
treated for osteoporosis compared to those with-
out (women 43.2 vs 18.1%, ∅ 25.1%, CI 21.5 to
28.8, and men 25.9 vs 7.3%,∅ 18.7%, CI 13.3 to
24.6). However, less than half (42.6%) of all pre-
treated patients were taking a bone active sub-
stance.
Treatment after the current fragility fracture:
After the acute fragility fracture reported in the
present study, 1576 patients (43.0%) received any
treatment against osteoporosis, which represents
an absolute increase in osteoporosis treatment
rate of 19.8% (17.7 to 21.9) compared to before
the fracture event in both genders. The osteo-
porosis treatment rate increased by 20.6% (18.1
to 23.0) in women and 17.4% (13.6 to 21.1) in
men as shown in table 2. Patients with a positive
history of previous fracture during adulthood, i.e.,
patients currently presenting with a second frac-
ture or more, were signiﬁcantly more likely to get
any treatment against osteoporosis than those
without (58.9 vs 41.1%,∅ 17.8%, CI 13.9 to 21.7,
and 45.9 vs 23.5%,∅ 22.4%, CI 15.5 to 29.2, for
women and men, respectively). Similarly, a posi-
tive history of previous fracture increased the
likelihood of getting treatment with a bone active
substance (36.6 vs 17.9%, ∅ 18.7%, CI 15.1 to
22.3, and 22.6 vs 9.9%, ∅ 12.7%, CI 7.3 to 18.5,
in women and men, respectively). However, only
half (50.3%) of all treated patients received a
“state of the art” combination of a bone active
substance with or without supplements, corre-
sponding to 21.6% (24.0% of the women and
13.8% of the men) of all eligible being adequately
treated after an acute fragility fracture. When
given calcium and/or vitamin D supplements,
85.3% of the patients received a combination of
both.When given a bone active substance, 89.3%
of the patients received a bisphosphonate, gener-
ally an oral bisphosphonate. Figure 4 shows the
relative proportions of patients adequately diag-
nosed and subsequently treated by 10-year age
groups.
Women Before current After current Absolute difference
fracture fracture after vs before
All patients (n = 2797, 100.0%) N % N % ∆ (%) 95%CI
Any treatment 736 26.3% 1312 46.9% 20.6% 18.1 to 23.0
Calcium and/or vitamin D supplements only 415 14.8% 640 22.9% 8.0% 6.0 to 10.1
Bone active substance ± supplements 321 11.5% 672 24.0% 12.5% 10.6 to 14.5
Positive history of previous fracture (n = 919)
Any treatment 397 43.2% 541 58.9% 15.7% 11.1 to 20.1
Calcium and/or vitamin D supplements only 189 20.6% 205 22.3% 1.7% 2.0 to 5.5
Bone active substance ± supplements 208 22.6% 336 36.6% 13.9% 9.8 to 18.0
No or unknown history of previous fracture (n = 1878)
Any treatment 339 18.1% 771 41.1% 23.0% 20.2 to 25.8
Calcium and/or vitamin D supplements only 226 12.0% 435 23.2% 11.1% 8.7 to 13.5
Bone active substance ± supplements 113 6.0% 336 17.9% 11.9% 9.9 to 13.9
Men Before current After current Absolute difference
fracture fracture after vs before
All patients (n = 870, 100.0%) N % N % ∆ (%) 95%CI
Any treatment 113 13.0% 264 30.3% 17.4% 13.6 to 21.1
Calcium and/or vitamin D supplements only 72 8.3% 144 16.6% 8.3% 5.2 to 11.4
Bone active substance ± supplements 41 4.7% 120 13.8% 9.1% 6.4 to 11.8
Positive history of previous fracture (n = 266)
Any treatment 69 25.9% 122 45.9% 19.9% 11.8 to 27.8
Calcium and/or vitamin D supplements only 43 16.2% 62 23.3% 7.1% 0.4 to 13.9
Bone active substance ± supplements 26 9.8% 60 22.6% 12.8% 6.6 to 19.1
No or unknown history of previous fracture (n = 604)
Any treatment 44 7.3% 142 23.5% 16.2% 12.3 to 20.3
Calcium and/or vitamin D supplements only 29 4.8% 82 13.6% 8.8% 5.6 to 12.1
Bone active substance ± supplements 15 2.5% 60 9.9% 7.5% 4.9 to 10.3
Any treatment = calcium and/or vitamin D supplements and/or any bone active substance
Bone active substance ± supplements = bisphosphonate, SERM, teriparatide, hormone replacement therapy or androgens, or calcitonin,
with or without calcium and/or vitamin D supplement.
Table 2
Treatment rate before
and after inclusion
for fragility fracture,
by history of previ-
ous fracture and
gender (n = 3667).
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The aim of the present prospective cohort
study which included 3667 patients from a repre-
sentative sample of 8 Swiss hospitals was to pro-
vide a snapshot of the current situation regarding
patient characteristics, current diagnostic workup
and treatment patterns of osteoporosis in patients
50 years old or more and presenting to the emer-
gency ward with a fracture.
Fractures were three times more frequent in
women than in men. Fractures tended to be more
frequent with increasing age in both genders, and
this effect was more pronounced in women than
in men. Considering that the number of persons
alive decreases with age, this observation is con-
sistent with an exponential increase of fragility
fractures with age and with a delayed increase by
approximately 10 years in men compared to
women [2, 21].
Approximately one third of all patients had
one or more previous fractures during adulthood
before inclusion. Fractures at inclusion were dis-
tributed across the whole range of possible frac-
tures and evenly distributed between lower limbs,
upper limbs and the axial skeleton, albeit fractures
of the upper limbs were more frequent than other
fractures in women and more frequent in women
than in men, which is consistent with earlier ob-
servations [2]. Eighty percent of the patients were
hospitalised, with a mean length of stay of 9.1
days. Thereafter, only 50% of these patients were
discharged home. For a signiﬁcant proportion of
hospitalised patients, the fracture event resulted
in a transient or permanent loss of independence,
approximately one third being discharged to a re-
habilitation clinic and one sixth being institution-
alised. This observation is consistent with the ob-
servation according to which recent osteoporotic
fractures have a signiﬁcant impact on health re-
lated quality of life in postmenopausal women
[22] and men [23, 24].
The “classical” osteoporotic fractures (distal
forearm, spine, and femoral neck and trochanter)
Discussion
Women (N = 2797)
Men (N = 870)
Figure 4
Fragility fractures,
subsequent DXA
measurement and
treatment rates in
women and men, by
10-year age-groups.
* Any treatment =
calcium and/or vita-
min D supplements
and/or any bone ac-
tive substance (bis-
phosphonate, SERM,
teriparatide, hormone
replacement therapy
or androgens, calci-
tonin).
age-groups (years)
age-groups (years)
Total patients
Patients with DXA
measurement
Patients with any
treatment after DXA
Patients with a bone
active substance
after DXA
Total patients
Patients with DXA
measurement
Patients with any
treatment after DXA
Patients with a bone
active substance
after DXA
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represented 55.7 and 49.8% of all fragility frac-
tures in women and men respectively. These per-
centages are lower than previously reported from
Swiss hospitalisation data (66.3 and 59.0% for
women and men, respectively) [2]. Several possi-
ble explanations may account for this observation:
First, the present data report all fragility fractures,
whether hospitalised or not; second, the deﬁni-
tion of an osteoporotic fracture in the Swiss hos-
pitalisation data was based on attribution rates,
which may underestimate the proportion of os-
teoporotic fractures in non typical localisations;
and third, fragility fractures may become increas-
ingly recognised as osteoporotic, independently
of their localisation, acknowledging the increas-
ing awareness of osteoporosis as a systemic dis-
ease.
A BMD measurement by DXA is indicated in
all patients presenting with a fragility fracture [9].
In the present survey, diagnostic workup was gen-
erally poor, DXA measurement being reported in
only 31.4% of all patients presenting with a
fragility fracture after the age of 50 years, and was
even more so when considering that a dedicated
nurse was allocated to the project in all participat-
ing centres. However, this result is better than the
previously published ﬁndings of a pilot study
which relied on direct information to the refer-
ring physicians and did not involve a dedicated
nurse in which a DXA measurement was per-
formed in only 12.6% of the patients presenting
with a fracture at the orthopaedic ward [25]. It
cannot be excluded that, in some patients, BMD
was measured after discharge by their family
practitioner, as recommended in some discharge
letters. Although this seems a possible scenario,
this number is expected to be small based on pilot
experience and on the fact that compliance with
osteoporosis management guidelines in fracture
patients was previously shown to be generally low
[10, 26].
In the present survey, osteopenia or osteo-
porosis as deﬁned by theWHO [1] was identiﬁed
as underlying disease in approximately 80% of the
patients presenting with a fragility fracture. This
ﬁnding is consistent with reports from other Eu-
ropean countries such as Scotland [16, 27], France
[28] and the Netherlands [13] but contrasts with
one previous ﬁnding reporting only 6.4% of post-
menopausal women with fracture having a T-
score of –2.5 or less, using peripheral measure-
ment devices [29].
The overall osteoporosis treatment rate be-
fore current fragility fracture was low (23.2%),
but was higher in patients who had experienced a
previous fracture (39.3%) compared to those who
had not (15.4%). However, only half (19.7%) of
these high risk patients with a positive history of
previous fracture, were adequately treated with a
bone active substance while the other half
(19.6%) were treated with calcium and/or vitamin
D supplements only. Although the observation
that osteoporosis treatment rate almost doubled
from 23.2% before the current fracture to 43.0%
thereafter is encouraging, the share of those
treated with a bone active substance remained un-
changed at approximately 50% of all treated.
Several drug classes have proven higher efﬁ-
cacy than calcium and vitamin D supplements in
reducing fracture risk. Bisphosphonates were
shown to reduce fracture risk at all clinically rele-
vant sites, including the hip, in adequately de-
signed primary fracture endpoint trials in post-
menopausal women, with consistent observations
for men with osteoporosis [30]. In addition to
their proven efﬁcacy in reducing fracture risk,
these interventions were considered cost-effective
in women and men aged 65 years or older [31,
32]. Whether simpliﬁed patient identiﬁcation
measures, such as questionnaires for determina-
tion of the 10-year absolute fracture risk of an
individual patient [33] will contribute to improve
treatment penetration remains to be established.
Considering that overall only one ﬁfth of the pa-
tients presenting with a fragility treatment are
getting adequate treatment according to guide-
lines, osteoporosis should be considered as largely
undertreated in Switzerland, a ﬁnding which is
unfortunately consistent with previous reports
from other European countries [10, 26, 28, 34–
36].
In the present survey, men accounted for
25.4% of all included fragility fractures, 21.2% of
all DXA measurements performed, and 15.2% of
all patients treated with at least a bone active sub-
stance. This indicates that even after a fragility
fracture, osteoporosis identiﬁcation and treat-
ment remains lower in men than in women, possi-
bly due to lower disease awareness at the physi-
cian and the patient level. Osteoporosis is increas-
ingly being recognised as an important cause of
morbidity and mortality in older men, represent-
ing a growing public health issue in industrialised
countries [8, 37]. Approximately 25–35% of hip
fractures were shown to occur in men [2, 37] with
an associated mortality twice of that in women
[38]. Furthermore, prevalent vertebral deformity
was shown to predict both increased mortality
and increased fracture incidence during the fol-
lowing decade also in men [8].Taking into consid-
eration 1) the already considerable and increasing
burden of osteoporosis in men, 2) that long-term
risk of subsequent fracture following an initial
fragility fracture is similar in both genders [6],
3) that diagnostic and therapeutic recommenda-
tions aiming at reducing fracture risk are similar
in both genders, and 4) that the outcome of frac-
ture is similar in both genders, as shown in this
survey, fragility fractures in men should deserve
the same level of clinical attention as in women.
Overall, management of patient with frac-
tures was not satisfactory and not in line with cur-
rent expert recommendations. Recent publica-
tions have shown that these results can be im-
proved by implementing adequate structures with
dedicated personnel and streamlined patient
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management processes. A clinical osteoporosis
pathway for the management of patients with low
trauma fracture was set up in Geneva, Switzerland
[15]. In that setting and in a selected population
of 384 patients recruited over 3 years, 63% of the
patients had BMD measured by DXA, 86% were
identiﬁed with low bone mass or osteoporosis,
33% were proposed a speciﬁc antiosteoporotic
therapy, and two thirds of them were still on ther-
apy 6 months later [15]. In a Dutch fracture and
osteoporosis clinic, 65% of the admitted patients
with fracture followed the diagnostic procedure,
40% were identiﬁed as osteoporotic, and treated
with a bone active substance (generally a bisphos-
phonate) with a low discontinuation rate of 11%
after 3 months [13]. In addition, experience from
other countries has shown that consistent imple-
mentation of osteoporosis diagnostic and treat-
ment measures might reverse the predicted in-
crease of osteoporotic fractures [3] despite the
aging of the population [39]. In order to improve
the quality of fracture patient management, sev-
eral approaches have been proposed and imple-
mented by the participating hospitals, ranging
from additional mandatory ﬁelds for osteoporosis
diagnosis and treatment in the electronic patient
ﬁle to the creation of bone disease management
units with dedicated personnel and predeﬁned
workﬂows and pathways involving the trauma/or-
thopaedic ward [40]. The impact on quality of
medical care of these measures will be assessed by
comparing achieved results with the present base-
line.
This survey has several limitations. By design,
the aim was to collect consecutive patients in all
participating centres. However, across and even
within centres, patients were not always consis-
tently included. Although a dedicated nurse was a
pre-requirement of the survey, the time the nurses
could allocate to the project in addition to their
other duties varied by centre and over time,
sometimes leading to incomplete data collection,
e.g., when a follow-up was needed with the treat-
ing physician.This precluded a detailed analysis on
the individual contribution of dedicated person-
nel to the outcome. One particular concern was
the low recruitment rate in one centre (35% com-
pared to 82% in the remaining centres) for which
the investigators indicated that the reason for un-
willingness to participate was the need for written
informed consent required by the cantonal ethical
review board. It can only be speculated why some
patients were reluctant to give their written in-
formed consent, although no data other than
those from routine workup were collected: avail-
ability of the consent letter at the ward, additional
time investment, chosen wording, collection of
the signed consent letters, and integration of an
additional step in daily routine are possible pit-
falls. However, a sensitivity analysis showed that
exclusion of these patients from the analysis did
not signiﬁcantly change the results of the present
study with regard to mean age, gender distribu-
tion, history of previous fracture, DXA measure-
ment rate, mean lowest T-score, treatment rates
(any treatment and treatment with a bone active
substance) before and after current fracture. Only
hospitalization rate increased when excluding the
outlier (82.6 vs 80.2%, D 2.4%, CI 0.6 to 4.2).
Therefore, the site was included in the analysis.
Osteoporosis treatment rate increased after the
survey. The inclusion dates of the individual pa-
tients were not collected, which precluded an
analysis of whether the rates of DXA measure-
ment and drug treatment had progressed during
the survey, as a result of the physicians being
informed that their osteoporosis management
behaviour was recorded. The Hawthorne effect is
well-known, and generally accounts for behaviour
improvements [41]. Therefore, the present results
may overestimate actual diagnosis and treatment
rates in osteoporosis.
In conclusion, osteoporosis remains widely
underdiagnosed and undertreated in Switzerland,
even in a high risk population of elderly patients
with fragility fractures. This fact is even more
worrisome for men. Quality improvement meas-
ures for the management of patients presenting
with fragility fractures are urgently needed and
should rely on an approach integrating individu-
als at risk, treating physicians and hospitals. Dedi-
cated hospital structures and personnel, with
process ownership and taking responsibility for
implementation and outcome improvement, or a
fracture liaison service may be key success factors.
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